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Introduction
The glycosphingolipid (GSL) storage diseases are caused
by genetic disruption in the lysosomal degradation path-
way of GSLs (1, 2). These disorders include Tay-Sachs
disease, Sandhoff ’s disease, Gaucher’s disease, Fabry’s
disease, Krabbe’s disease, and several others. In most of
these diseases, GSLs accumulate to massive levels in cells,
particularly in neurons, causing neurodegeneration and
a shortened life span.
Neurons are primary sites of GSL storage because
gangliosides — sialylated GSLs — are normal and rel-
atively abundant constituents of neuronal mem-
branes (1). GSLs are synthesized by the sequential
addition of monosaccharides to ceramide by multiple
Golgi membrane–bound glycosyltransferases (Fig. 1).
The relatively simple gangliosides GM3 and GD3 are
produced by the monosialylation and disialylation,
respectively, of lactosylceramide. Synthesis of the
more complex gangliosides is dependent on the sub-
sequent action of β1,4-N-acetylgalatosaminyltrans-
ferase (GalNAcT, GM2/GA2 synthase; EC 2.4.1.94).
After transport to the plasma membrane, the GSLs are
ultimately delivered to lysosomes for degradation.
Their degradation involves the stepwise removal of
individual saccharides through the concerted action
of lysosomal enzymes and activator proteins. In the
GSL storage diseases, the absence of particular
enzymes or activator proteins blocks the degradation
pathway and leads to accumulation of GSL substrates
unique to each disease .
An emerging strategy for the treatment of these diseases
is substrate deprivation therapy (3, 4). In this approach, a
specific inhibitor of GSL biosynthesis is used to reduce
lysosomal storage by lowering the synthetic rate to more
closely approximate the compromised rate of degrada-
tion. Platt et al. (4) demonstrated the potential validity of
this approach with the oral administration of N-
butyldeoxynojirimycin (NB-DNJ), an inhibitor of the first
glycosyltransferase in GSL synthesis, to a Tay-Sachs dis-
ease mouse model that had central nervous system (CNS)
storage of GSLs, but which was without clinical manifes-
tations. This regimen substantially lowered brain levels of
abnormally stored GSLs in the model mice.
Although the results suggest that the strategy may
ultimately lead to an effective treatment for the GSL
storage diseases, a number of important issues
remain. These include the expected clinical benefit of
the therapy, potential deleterious effects of GSL
depletion, and the diseases most suitable for the ther-
apy. We have addressed these issues by constructing a
genetic model of substrate deprivation therapy for a
GSL storage disease through the establishment of
mice with simultaneous blocks in GSL synthesis and
degradation pathways.
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Inherited defects in the degradation of glycosphingolipids (GSLs) cause a group of severe diseases
known as GSL storage disorders. There are currently no effective treatments for the majority of these
disorders. We have explored a new treatment paradigm, substrate deprivation therapy, by constructing
a genetic model in mice. Sandhoff ’s disease mice, which abnormally accumulate GSLs, were bred with
mice that were blocked in their synthesis of GSLs. The mice with simultaneous defects in GSL synthe-
sis and degradation no longer accumulated GSLs, had improved neurologic function, and had a much
longer life span. However, these mice eventually developed a late-onset neurologic disease because of
accumulation of another class of substrate, oligosaccharides. The results support the validity of the sub-
strate deprivation therapy and also highlight some limitations.
J. Clin. Invest. 103:497–505 (1999).
Methods
Generation of GalNAcT–/– and Hexb–/– GalNAcT–/– double knockout
mice. Genomic clones from a 129/Sv strain library (catalog no.
946306; Stratagene, La Jolla, California, USA) containing the
mouse GalNAcT gene were isolated by using a mouse GalNAcT
cDNA probe (5). One genomic clone was used to construct the
targeting vector containing a 7.8-kb genomic DNA sequence.
The targeting vector (20 µg) was linearized and electroporated
into 2 × 107 TC1 embryonic stem (ES) cells (6) in a volume of 0.8
ml at 400 V and 25 µF (Bio-Rad Laboratories Inc., Hercules, Cal-
ifornia, USA). The G418, ganciclovir-resistant ES cells were
obtained and screened by Southern analysis. Chimeric mice were
established from targeted ES cells as described (6).
Male Hexb–/– mice were crossed to female GalNAcT–/– mice to
generate Hexb+/– GalNAcT+/– mice. These double heterozygous
mice were crossed to generate Hexb–/– GalNAcT–/– double
knockout mice. The knockout mice were a combination of
C57BL/6 and 129/Sv strains.
Behavioral analysis. Sixty-four mice (10 Hexb+/+ GalNAcT+/+: 6
males, 4 females; 16 Hexb+/+ GalNAcT–/–: 8 males, 8 females; 14
Hexb–/– GalNAcT+/+: 10 males, 4 females; 10 Hexb–/– GalNAcT+/–: 3
males, 7 females; and 14 Hexb–/– GalNAcT–/–: double knockouts,
7 males, 7 females) completed 8 weeks of behavioral testing.
Mice that survived longer completed additional behavioral test-
ing. All mice were 11 weeks old at the start of behavioral testing.
Mice were group-housed by gender, 2 to 5 per cage. Food and
water were freely available in the home cages. The colony room
was maintained on an artificial 12-h light/12-h dark cycle, with
lights on at 6 am.
Rotorod. The ability to maintain balance on a rotating cylinder
was measured with a commercially available rotorod apparatus
(Model 7650; Ugo Basile, Varese, Italy). The cylinder was 3.2 cm
in diameter with a surface of scored plastic. Mice were confined
to a section of the cylinder 6.0 cm long by black Plexiglas
dividers. Each mouse was placed on the cylinder, which
increased rotation speed from 5 to 40 rpm over a 5-min period.
The primary measure of interest was the latency at which mice
either fell off the rotorod or clung to the rod while it turned one
full rotation. Mice that did not fall or cling during the 300-s trial
period were removed and given a score of 300. Rotorod per-
formance was measured once every 2 weeks for 8 weeks.
Righting reflex. Mice were tested at 17 and 23 weeks old. Right-
ing reflex was measured by turning the mouse on its back on a
flat stainless steel surface. Latency to turn itself upright was
recorded. Mice not righting themselves within 10 s were turned
right-side up and assigned a score of 10.
Statistical analysis. Group comparisons were made using
ANOVA. Analyses of performance over time were made using
repeated measures ANOVA (RMANOVA), with genotype as a
between-subjects factor and age at testing as the repeated
measure. Follow-up comparisons of repeated-measures data
were made using single-factor and two-group RMANOVA or
Bonferroni-corrected t tests.
Biochemical analysis. The analysis of lipids followed a method
described previously (7). Fluorophore-assisted carbohydrate
electrophoresis (FACE) was used for urinary oligosaccharide
analysis with a kit from Glyko Inc. (Novato, California, USA)
(8). Urine samples were normalized by using a creatinine quan-
titative kit (catalog no. 555-A; Sigma Chemical Co., St. Louis,
Missouri, USA). Aliquots of urine were incubated overnight at
37°C with the ANTS (8-aminonaphthalene 1,3,6-trisulfonic
acid, disodium salt) reagent followed by high-resolution PAGE
and visualization using the FACE imaging system (Glyko Inc.).
Pathology. Mice with different genotypes and age were studied,
including two 4.5-month-old Hexb+/+ GalNAcT–/–, two 4.5-month-
old Hexb–/– GalNAcT+/+, two 4.5-month-old Hexb–/– GalNAcT+/–,
two 4.5-month-old Hexb–/– GalNAcT–/–, two 8.5-month-old
Hexb+/+ GalNAcT–/–, and two 8.5-month-old Hexb–/– GalNAcT–/–.
Mice were anesthetized and perfused with phosphate-buffered
4% paraformaldehyde (pH 7.4). The brain, spinal cord, and pieces
of visceral organs were processed for paraffin sections, cut and
stained with Solochrome/eosin, hematoxylin/eosin (H&E),
Luxol fast blue/periodic acid-Schiff, and Bielschowsky’s stains.
The tissues for frozen sections were immersed in fixative
overnight. After cryoprotection by immersion in 0.1 M phos-
phate buffer (pH 7.4) containing 20% sucrose, the tissues were
snap frozen and sections were stained with PAS. For electron
microscopic analysis, tissues were processed for embedding in
plastic resin. Sections (1 µm thick) were cut and stained with
toluidine blue. Appropriate areas for further thin sectioning were
selected under light microscopy and trimmed for ultrathin sec-
tioning. Sections were double stained with uranyl acetate and
lead citrate and examined with a Zeiss 10a electron microscope.
Immunochemistry. The mice examined were 4.5-month-old
wild-type, Hexa–/–, Hexb–/– GalNAcT+/+, and Hexb–/– GalNAcT–/–
mice. The brains, spinal cords, kidneys, livers, and spleens
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Figure 1
Partial synthesis pathway of GSLs. GA2 glycolipid, GalNAcβ1′
4Galβ1′ 4Glcβ1′ 1Cer, and GM2 ganglioside, GalNAcβ1′
4(NeuAcα2′ 3)Galβ1′ 4Glcβ1′ 1Cer, are highlighted as the
major glycolipid storage products in the Sandhoff ’s disease
model mice. GM3: NeuAcα2′ 3Galβ1′ 4Glcβ1′1Cer; GD3:
NeuAcα2′ 8NeuAcα2′ 3Galβ1′ 4Glcβ1′1Cer; GD2: Gal-
NAcβ1′ 4(NeuAcα2 ′ 8NeuAcα2′ 3)Galβ1′ 4Glcβ1′ 1Cer.
Note that the gene encoding GalNAcT is known as Galgt1
and was formally known as Ggm2 (5). Cer, ceramide; GSLs,
glycosphingolipids.
were removed, embedded in O.C.T. compound (Sakura
Finetek USA Inc., Torrance, California, USA) and quickly frozen
in liquid nitrogen.
GM2 and N-linked oligosaccharide storage was detected by an
indirect immunofluorescence method using anti-GM2 (9) anti–N-
linked oligosaccharide (10) monoclonal antibody. The latter anti-
body binds N-linked oligosaccharides with a nonreducing ter-
minal β-linked GlcNAc residue. Frozen sections (7 µm thick)
were fixed in cold acetone for 10 min and air dried. After rehy-
dration in PBS, the sections were incubated with 5% normal goat
serum in PBS for 1 h. The culture supernatant from mouse
hybridomas GMB28 (9) (anti-GM2) and OMB4 (10) (anti–N-
linked oligosaccharide) were then applied to the sections, and the
slides were incubated at room temperature for 1 h. After rinsing
with PBS, the sections were incubated with FITC-labeled
anti–mouse IgM antibody (Sigma Chemical Co.) for 1 h. The flu-
orescence was observed under a Leica fluorescence microscope.
Results
Experimental design. We have previously produced a clin-
ically and pathologically accurate mouse model of Sand-
hoff ’s disease through the disruption of the gene (Hexb)
encoding the β subunit of β-hexosaminidase (11). These
mice are deficient in both β-hexosaminidase A (αβ) and
B (ββ), the major forms of lysosomal β-hexosaminidase.
Their nearly total β-hexosaminidase deficiency — only a
very small amount of β-hexosaminidase S (αα ) remains
— renders the mice compromised in their ability to
degrade GM2 ganglioside and the related GA2 glycolipid.
As in the human disease, these glycolipids accumulate in
neurons causing apoptosis (12), progressive loss of
motor behaviors, and a severely shortened life span (11).
To investigate consequences of totally eliminating GM2
ganglioside and GA2 glycolipid synthesis in Sandhoff’s dis-
ease mice, we first generated mice deficient in GalNAcT.
GalNAcT transfers N-acetylgalactosamine onto glycolipid
acceptors to produce complex glycolipids, including GA2
and GM2 (Fig. 1). The GalNAcT gene was disrupted by a
replacement-type targeting vector in which exon 6, exon
7, and part of exon 8 were deleted and replaced with the
MC1NeoPolyA (13) selection cassette (Fig. 2a). GalNAcT–/–
mice were obtained through heterozygous matings with a
frequency expected from mendelian inheritance, suggest-
ing the absence of embryonic lethality. The inactivation of
the GalNAcT gene was proven by Northern analysis: no
GalNAcT-related transcripts were detected in the brain and
liver of GalNAcT–/– mice (not shown).
Because of the absence of GalNAcT, these mice were
unable to synthesize complex gangliosides normally
present in the brain (Fig. 2c, lane 1). The complex gan-
gliosides (Fig. 2c, lane 1) were replaced by GM3, GD3, and
lactosylceramide in the brains of the GalNAcT–/– mice
(Fig. 2c, lanes 3 and 4), structures synthesized before the
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Figure 2
Targeted disruption of the GalNAcT locus and
generation of Hexb–/– GalNAcT–/– double
knockout mice. (a) The structure of the mouse
GalNAcT targeting vector is on the top, the
structure of the mouse GalNAcT locus is in the
middle, and the predicted structure of the
homologously recombined locus is on the
bottom. (b) Genotyping of mouse offspring
from the Hexb+/– GalNAcT+/– double heterozy-
gous mating. Genomic DNA was isolated
from mouse tails, digested with HindIII
endonuclease, electrophoresed on a 1%
agarose gel, and transferred to a nylon mem-
brane. The hybridization was performed with
both the Hexb probe (11) and GalNAcT probe
simultaneously, a. Wild-type Hexb locus yield-
ed a 3-kb HindIII band. Disrupted Hexb locus
yielded a 4-kb HindIII band. Wild-type GalN-
AcT locus showed an 8-kb HindIII band. Tar-
geted GalNAcT locus showed a 10-kb HindIII
band. (c) TLC analysis of acidic (a; lanes 1 and
3) and neutral (n; lanes 2 and 4) lipid frac-
tions from brains of GalNAcT+/+ mice and 
GalNAcT–/– mice.
block at GalNAcT (Fig. 1).
Despite the striking absence of complex ganglioside
structures, the GalNAcT–/– mice were grossly normal at
12 months old. This finding is similar to the previously
generated GalNAcT knockout mice, in which the neo
gene was simply inserted into exon 4 of the gene (14),
even though our mice were created with a more severe,
multiexon gene deletion.
A major phenotypic finding related to the absence of
complex gangliosides in the GalNAcT–/– mice was male
infertility caused by degeneration of seminiferous tubules
(not shown). Female GalNAcT–/– mice were fertile.
Life span and behavioral analysis. We generated Hexb–/– Gal-
NAcT–/– double knockout mice through matings of double
heterozygotes (Fig. 2b). In the same crosses, Hexb–/– GalN-
AcT+/+ and Hexb–/– GalNAcT+/– mice were also obtained. The
life span of each group of mice (n = 10) was evaluated (Fig.
3a). The mice in the Hexb–/– GalNAcT+/+ group died
120–150 days after birth, following the onset of a rapid
neurodegenerative disease course (11). The group of
Hexb–/– GalNAcT+/– mice showed a very similar but slightly
delayed disease course; they lived until 149–184 days after
birth, a significantly longer period than the Hexb–/– GalN-
AcT+/+ mice (P =  0.0002). During the 300-day duration of
the experiment, 9 of 10 double knockout mice remained
viable; a double knockout mouse died at 170 days after
birth for unknown reasons. All of the Hexb+/+ GalNAcT–/–
mice survived the testing period.
Mice of different genotypes were tested on two behav-
ioral tasks, righting reflex and rotorod, that have been
proven to monitor the progressive disease course of the
Hexb–/– mice (11, 15). The Hexb–/– mice likely become
progressively impaired in these tasks as a result of CNS
storage, motor neuron damage, and muscle wasting evi-
dent in the disease (16). In the righting reflex task, the
mice are placed on their backs, and the time to right
themselves is recorded. Normal mice right themselves
immediately. As they age, the Hexb–/– mice show a decline
in righting reflex. In the rotorod task, a measure of
motor function and coordination, the time that the mice
can remain on a rotating cylinder is determined. The
Hexb–/– mice show a progressive decline in their ability to
remain on the rotorod (11).
There were significant differences across groups on the
righting reflex, measured at 17 weeks old (F4,59 = 12.12, P
< 0.0001) (Fig. 3b). Post hoc analyses showed that the
Hexb–/–GalNAcT+/+ mice had a significantly impaired
righting reflex, compared with all other groups (all t’s >
2.99; all P’s < 0.0068). None of the other group compar-
isons were significant at 17 weeks old, showing that the
double knockout and Hexb–/– GalNAcT+/– mice were not
impaired at this time. However, at 23 weeks old, the
Hexb–/– GalNAcT+/– mice had a significantly impaired
righting reflex, compared with all other groups (all t’s >
4.12; all P’s < 0.0013). None of the other group compar-
isons was significant at this age demonstrating that the
double knockout mice were not impaired in this task. By
23 weeks old, the Hexb–/–GalNAcT+/+ mice had died.
As shown in Fig. 3c, rotorod performance — a measure
of balance and mobility — during the period that the
Hexb–/– GalNAcT+/+ mice remained viable (11–17 weeks)
differed greatly across the five groups (F4,59 = 9.03; P <
0.0001) and over the six-week testing period (F3,177 =
10.17; P < 0.0001). In addition, there was a significant
Genotype X Age interaction (F12,177 = 3.32; P = 0.0002),
indicating that performance of some mice deteriorated
significantly over the six-week testing period, while per-
formance of other mice did not change significantly.
Planned follow-up comparisons showed that rotorod
performance of the Hexb–/– GalNAcT+/+ mice was signifi-
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Figure 3
Life span and behavioral testing. (a) Survival of the Hexb–/– mice with differ-
ent GalNAcT backgrounds. Each group contained 10 mice. (b) Mean (±
SEM) righting reflex for Hexb+/+ GalNAcT+/+ (n = 10), Hexb+/+ GalNAcT–/– (n =
16 at 17 weeks; n = 15 at 23 weeks), Hexb–/– GalNAcT+/+ (n = 14), Hexb–/– Gal-
NAcT+/– (n = 10 at 17 weeks; n = 5 at 23 weeks), and Hexb–/– GalNAcT–/– dou-
ble knockouts (n = 14). All Hexb–/– GalNAcT+/+ mice were dead by 23 weeks
old. Hexb–/– GalNAcT+/+ mice had a significantly impaired righting reflex com-
pared with all other groups at 17 weeks old. Hexb–/– GalNAcT+/– mice had a
significantly impaired righting reflex compared with all other groups at 23
weeks old. (c) Mean (± SEM) time to fall off the rotorod. Group size at all
time points: Hexb+/+ GalNAcT+/+ (n = 10), Hexb+/+ GalNAcT–/– (n = 16), Hexb–/–
GalNAcT+/+ (n = 14), Hexb–/– GalNAcT+/– (n = 9), and Hexb–/– GalNAcT–/– dou-
ble knockouts (n = 14) were tested. The lowered variability of the Hexb–/– Gal-
NAcT+/+ and Hexb–/– GalNAcT+/– mice at later times probably reflects their
worsening condition and their limited ability to perform the task.
cantly worse than that of the control mice (F1,22 = 15.57;
P < 0.0001), replicating results from previous studies (7,
11, 15). Rotorod performance of the double knockout
mice was significantly worse than that of the control
mice (F1,22 = 9.22; P = 0.0061). However, the performance
of the double knockout mice remained stable with
increasing age, compared with the rapidly deteriorating
performance of the Hexb–/– GalNAcT+/+ mice (F3,78 = 4.86;
P = 0.0038). The Hexb–/– GalNAcT+/– group performed sig-
nificantly better overall than both the Hexb–/– GalNAcT+/+
group (F1,22 = 16.99; P = 0.0004) and the double knock-
out group (F1,22 = 8.49; P = 0.008). However, the per-
formance of the Hexb–/– GalNAcT+/– mice deteriorated
much faster than that of the double knockout mice from
11 to 17 weeks old (F3,66 = 5.87; P = 0.0013). The rate of
deterioration in the Hexb–/– GalNAcT+/– mice was not dif-
ferent from that of the Hexb–/– GalNAcT+/+ mice (F3,66 =
0.96; P = 0.419). There was no significant difference in
rotorod performance between the normal controls and
the Hexb+/+ GalNAcT–/– groups (F1,24 = 0.34; P = 0.566)
during this time period.
At 21 weeks old, the last testing time that included the
Hexb–/– GalNAcT+/– mice, there were significant group dif-
ferences in rotorod performance (F3,44 = 18.57; P <
0.0001). Follow-up comparisons show that the double
knockout mice were now performing significantly better
than the Hexb–/– GalNAcT+/– mice (t21 = 2.80; P = 0.0108).
Rotorod performance of the control mice was signifi-
cantly better than both the double knockout mice (t22 =
5.32; P < 0.0001) and the Hexb–/– GalNAcT+/– mice (t17 =
8.16; P < 0.0001) at this age. There was no difference in
rotorod performance between the control and Hexb+/+
GalNAc–/– groups at 21 weeks old (t23 = 0.03; P = 0.979).
Beginning at about seven months old, the double
knockout mice began to display an ataxic gait that pro-
gressively worsened over time. At nine months old, these
mice exhibited severe phenotypic abnormalities, includ-
ing muscle wasting and hunched posture, while the
Hexb+/+ GalNAcT–/– mice appeared normal (Fig. 4).
Glycolipid and oligosaccharide accumulation. Brain gan-
gliosides were isolated from 4.5-month-old mice and
analyzed by thin-layer chromatography (TLC) (Fig. 5a).
Gangliosides of wild-type mice (Hexb+/+ GalNAcT+/+) con-
sisted primarily of GM1, GD1a, GD1b, and GT1b (Fig. 5a, lane
1). In Hexb–/– GalNAcT+/+ mice, extensive GM2 ganglioside
accumulation was superimposed upon the normal pat-
tern of complex gangliosides (Fig. 5a, lane 2). Hexb+/+ Gal-
NAcT –/– mice, unable to synthesize most complex gan-
gliosides, exhibited primarily GM3 and GD3 in the acidic
lipid fraction (Fig. 5a, lane 3). The acidic lipid pattern of
the double knockout mice was virtually indistinguish-
able from the Hexb+/+ GalNAcT –/– mice, with primarily
GM3 and GD3 gangliosides and no other abnormally accu-
mulating lipid species (Fig. 5a, lane 4). GM2 storage was
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Figure 5
Ganglioside accumulation and urinary oligosaccharide excretion. (a) The acidic fraction of sphingolipids from brain and liver tissues was sep-
arated by TLC. The ganglioside standards are indicated. (b) Urine was collected from 4-month-old mice of different genotypes. FACE was per-
formed to analyze urinary oligosaccharides. The size standards consist of glucose polymers. The bracket indicates the high-molecular-weight
oligosaccharides present in the Hexb–/– single knockout and Hexb–/– GalNAcT–/– double knockout urine but not the wild-type and GalNAcT–/– urine.
FACE, fluorophore-assisted carbohydrate electrophoresis.
Figure 4
Nine-month-old Hexb–/– GalNAcT–/– double
knockout mice shown with an age-matched
GalNAcT–/– single knockout mouse. Note the
hunched posture and disheveled condition of
the double knockout mouse.
also completely eliminated in the liver in the double
knockout mice (Fig. 5a, compare lanes 6 and 8). Likewise,
storage of related GA2 glycolipid was absent in the liver
and brain of the double knockout mice (not shown).
Because of a block in the degradation of N-linked
oligosaccharides caused by the absence of both β-hex-
osaminidase A and B, Sandhoff’s disease patients and
model mice excrete high-molecular-weight oligosaccharides
in their urine (15, 17) (Fig. 5b, lane 3). The double knockout
mice also excreted elevated levels of high-molecular-weight
oligosaccharides (Fig. 5b, lane 5), although the amount was
about half that in urine of the Hexb–/– GalNAcT+/+ mice. The
urinary oligosaccharides were sensitive to digestion with β-
hexosaminidase (not shown). Abnormal high-molecular-
weight oligosaccharides were not detected in the urine of
the Hexb+/+ GalNAcT–/– mice (Fig. 5b, lane 4).
Tissue storage of GM2 ganglioside and N-linked
oligosaccharides were assessed using anti-GM2 ganglio-
side (9) and anti–N-linked oligosaccharide monoclonal
antibody (10) (Fig. 6). The Tay-Sachs mouse model (18)
was examined as a comparison, because although they
accumulate GM2 ganglioside in tissues like the Sand-
hoff ’s disease mice, they should not accumulate
oligosaccharides because of the retention of β-hex-
osaminidase B, which is able to degrade N-linked
oligosaccharides but not GM2 ganglioside.
In both Hexb–/– (Sandhoff ’s disease) and Hexa–/– (Tay-
Sachs disease) mice, the distribution of GM2 storage
detected with antibody was consistent with previous
descriptions (11, 19, 20). GM2 immunostaining was
extensive and widely distributed in the CNS of Hexb–/–
mice (Fig. 6a, and data not shown). Positively stained
neurons were also found in the Hexa–/– mice, although
the GM2 distribution was restricted to particular regions
in the CNS (Fig. 6d, and data not shown). GM2 storage
was not apparent in the double knockout mice (Fig. 6g)
or wild-type mice (data not shown).
In Hexa–/– mice (Fig. 6, e and f) and wild-type mice (not
shown), anti-oligosaccharide immunostaining revealed
no significant storage of oligosaccharides in CNS or vis-
ceral organs. In Hexb–/– mice, oligosaccharide storage was
detected in cerebellar Purkinje cells (described below),
neuronal cells of the cerebral cortex, thalamic nuclei,
brainstem, spinal cord (Fig. 6c), and, weakly, in the hip-
pocampus. Double staining with anti-macrophage and
anti-oligosaccharide antibodies revealed that significant
storage of oligosaccharides was in microglial cells
throughout the CNS (not shown).
In the double knockout mice, the neuronal staining
with anti-oligosaccharide was detectable but reduced
when compared with the Hexb–/– GalNAcT+/+ mice.
Microglial cells storing oligosaccharides were easily
detected and found scattered throughout regions of the
brain and spinal cord (Fig. 6i).
In the visceral organs, oligosaccharide storage was
detectable in macrophages in the liver (Fig. 6, b and h)
and spleen as well as in renal tubular epithelium in both
the Hexb–/– GalNAcT+/+ and double knockout mice.
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Figure 6
GM2 ganglioside and oligosaccharide accumulation in tissues. Immunofluorescence staining of cerebral cortex, liver, and spinal cord with an anti-GM2
ganglioside monoclonal antibody (a, d, g) and an anti-oligosaccharide monoclonal antibody (b, c, e, f, h, i). ×100.
Pathologic analysis. Pathologic differences in 4.5-month-
old mice of different genotypes were evaluated. At this age,
the Hexb–/– GalNAcT+/+ mice showed severe axonal degen-
eration in the anterior column of the spinal cord (Fig. 7a,
arrows). By contrast, a similar section from the double
knockout mice appeared relatively normal (Fig. 7b). Using
combined Luxol fast blue (LFB) and periodic acid-Schiff
(PAS) staining, storage neurons containing large amounts
of blue-staining inclusions were readily observed through-
out the cerebral cortex of the Hexb–/– GalNAcT+/+ mice (Fig.
7c, arrows). Again, the double knockout mice did not show
this severe and conspicuous pathology (Fig. 7d). Perivas-
cular macrophages stained reddish-pink — indicative of
storage — were present in the brains of both double
knockout and Hexb–/– GalNAcT+/+ mice (Fig. 7, c and d;
arrowheads). Although massive neuronal inclusions were
not present in the double knockout (Hexb–/– GalNAcT–/–)
mice, some neurons were found to contain fine to coarse
vacuoles in their perikarya. These neuronal vacuoles were
examined by electron microscopy and compared with the
neuronal inclusions found in Hexb–/– GalNAcT+/+ mice. As
described previously, the inclusions of the Hexb–/– GalN-
AcT+/+ mice were electron-dense, membranous lamellar
structures consistent with GSL storage (11, 20) (Fig. 7e).
Vacuoles in the double knockout mice were very different
in appearance. They were relatively empty with some elec-
tron-dense debris (Fig. 7f). This appearance is consistent
with storage of water-soluble compounds such as
oligosaccharides. These pathologic changes described in
the double knockout mice were not observed in the
Hexb+/+ GalNAcT–/– mice (not shown).
A striking pathologic finding in the double knock-
out mice was an extensive loss of cerebellar Purkinje
cells by 8.5 months old (Fig. 8a), a time when these
mice were exhibiting severe ataxia. No evidence of
Purkinje cell degeneration was found in 8.5-month-old
Hexb+/+ GalNAcT–/– mice (Fig. 8b).
Using the anti-oligosaccharide antibody, cerebellar
Purkinje cells from double knockout (Fig. 8c) and
Hexb–/– GalNAcT+/+ mice (Fig. 8d) were found to display
a strong granular staining pattern indicative of abnor-
mal substrate accumulation. Little immunoreactivity
was seen in the molecular and granular layers. Purkin-
je cells from Hexa–/– mice and wild-type mice did not
show reactivity with the antibody (not shown).
Visceral pathology in the Hexb–/– GalNAcT+/+ mice,
which has been documented previously (11), included
vacuolated cells (storage macrophages) in the liver,
spleen, and kidney. Renal tubular epithelial cells were
also found to be vacuolated. Similar findings were also
present in the double knockout mice but not in the
Hexb+/+ GalNAcT–/– mice. The visceral pathology in the
double knockout and the Hexb–/– GalNAcT+/+ mice corre-
sponded well to the distribution of oligosaccharide stor-
age determined by immunostaining. In both the Hexb+/+
GalNAcT–/– and double knockout mice, degeneration of
seminiferous tubules in the testis was pronounced.
Discussion
Treatments that can reverse or alter progression of the
clinical manifestations for GSL storage diseases are lim-
ited and not effective for the majority of the disorders.
Enzyme replacement is an effective therapy for Type 1
Gaucher’s disease, a GSL storage disorder that is unique
by the absence of CNS manifestations (21, 22). For other
disorders that exhibit CNS involvement, enzyme replace-
ment has been difficult to implement thus far because
of the inability of enzyme to cross the blood–brain bar-
rier. Recently, bone marrow transplantation has been
reported to reverse CNS manifestations in the juvenile
form of Krabbe’s disease (23) but has been of little value
in other disorders (24).
Substrate deprivation therapy has some features that
make it an attractive treatment approach for the GSL
storage diseases. First, a single inhibitor may be used to
treat several of the disorders. NB-DNJ, the most inten-
sively studied drug, blocks the first glycosylation step in
the synthesis of glucose-based GSLs (25) and, thus,
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Figure 7
Comparison of pathology between double knockout (Hexb–/– GalNAcT–/–) and single knockout (Hexb–/– GalNAcT+/+) mice. (a and b) Plastic-embedded
spinal cord sections from (a) Hexb-/- GalNAcT+/+ and (b) Hexb–/– GalNAcT–/– mice were stained with toluidine blue. Arrows indicate axonal degenera-
tion. ×270. (c and d) Paraffin sections of cerebral cortex from (c) Hexb–/– GalNAcT +/+ and (d) Hexb–/– GalNAcT–/– mice. Sections were stained with LFB
and PAS. Neuronal inclusions were stained blue (arrows) and perivascular macrophages were stained reddish-pink (arrowheads). ×110. (e and f) Elec-
tron micrographs of anterior horn neurons of spinal cord from (e) Hexb–/– GalNAcT+/+ and (f) Hexb–/– GalNAcT–/– mice. ×11,000. Note differences in
the contents of storage vacuoles (v). LFB, Luxol fast blue stain; PAS, periodic acid-Schiff stain.
could be used to treat all storage diseases with defects in
the degradation of glucose-based GSLs. Second, NB-DNJ
crosses the blood–brain barrier to alter GSL storage lev-
els (4) and would potentially influence the CNS mani-
festations dominant in the majority of the diseases. And
finally, substrate deprivation therapy is noninvasive in
contrast to the other available treatments: bone marrow
transplantation and enzyme replacement.
We have developed a genetic model of substrate depri-
vation therapy for a GSL storage disease — Sandhoff ’s
disease — that has allowed investigation into questions
of potential efficacy and limitations. To achieve specific
and complete elimination of GSL storage, a GalNAcT
(Galgt1) knockout mouse was generated that was unable
to synthesize the majority of complex gangliosides.
Introduction of the disrupted GalNAcT gene into the
Sandhoff ’s disease background yielded mice with simul-
taneous blocks in GSL synthesis and degradation.
Extent of symptom elimination. The double knockout mice
were totally devoid of the major GSL storage substrates
normally found in Sandhoff’s disease mice. This resulted
in the absence of the massive neuronal storage and the very
severe pathology that is a defining feature of the disease
(11). The life span of the mice was extended from about
4–5 months to over 12 months, and the rapid neurode-
generation characteristic of the disease was not present.
The small reduction of GSL storage in the Hexb–/– Gal-
NAcT+/– mice increased their life span by only 18% and
illustrated the importance of balancing the rates of sub-
strate synthesis and degradation for the prevention of a
lysosomal storage disease (26). The Sandhoff ’s disease
model is similar to infantile disease forms, which have
very little GSL degradative activity. Only a nearly com-
plete reduction in GSL synthesis, as in the double knock-
out mice, would be expected to rescue the disease pheno-
type. The partial reduction of GSL synthesis afforded by
NB-DNJ would be anticipated to be more beneficial in
later onset forms of the diseases, which have significant
residual degradative activities, in contrast to the infantile
forms. Increased effectiveness of substrate deprivation
therapy in infantile diseases may be achieved by raising
degradative capacity through enzyme replacement, gene
therapy, or cell transplantation therapy.
The complete elimination of abnormal GSL storage in
the double knockout mice did not completely restore
neurologic function to control levels. Eventually the
double knockout mice began to exhibit ataxia that pro-
gressively worsened over time. The accumulation of a
second β-hexosaminidase substrate, N-linked oligosac-
charide, appears a likely contributor to the disease phe-
notype of double knockout mice. Although N-linked
oligosaccharide storage in Sandhoff ’s disease patients
has been well documented (17), its contribution to nerv-
ous system pathology and dysfunction has been difficult
to discern because of the dominant GSL storage. Our
studies with anti-oligosaccharide antibody indicate this
storage is widespread in the CNS and may contribute to
a striking loss of cerebellar Purkinje cells in the double
knockout mice. Oligosaccharide storage was also found
to be widely distributed in other tissues of the double
knockout mice and may be responsible for much of the
visceral pathology in Sandhoff ’s disease. Storage of
oligosaccharides in tissues and their excretion in urine
appeared to be more pronounced in the single knockout
Sandhoff ’s disease mice than in the double knockout
mice. The difference may be due to a nonspecific impair-
ment of lysosomal function by the additional storage of
GSLs in the Sandhoff ’s disease mice, as has been
described in Gaucher’s disease (27).
Proteoglycans are also substrates for β-hexosaminidase.
However, previous studies on mice with a total hex-
osaminidase deficiency (Hexa–/– Hexb–/–) indicated that β-
hexosaminidase S, present in Sandhoff ’s disease mice, is
sufficient to prevent significant pathology associated with
proteoglycan storage (7, 28). While the Sandhoff ’s and
double knockout mice (Hexb–/– GalNAcT–/–) are without
the characteristic pathology of mucopolysaccharidosis,
indicating that proteoglycans are likely not a major path-
ogenic factor, a minor contribution to pathogenesis by
this substrate is difficult to totally rule out.
Potential for secondary storage disease after substrate depriva-
tion therapy. In most of the GSL storage diseases, GSLs are
the exclusive substrate stored in tissues. With Tay-Sachs
disease, the presence of β-hexosaminidase B is sufficient
to preclude the storage of N-linked oligosaccharides that
occurs in Sandhoff ’s disease. Other disorders with exclu-
504 The Journal of Clinical Investigation | February 1999 | Volume 103 | Number 4
Figure 8
Purkinje cell degeneration in the Hexb–/– GalNAcT–/– double knockout
mice. (a and b) H&E staining of the cerebellum from (a) 8.5-month-old
double knockout and (b) 8.5-month-old GalNAcT–/– single knockout
mice. Arrows point out Purkinje cells. ×110. (c and d) Immunofluores-
cence staining of cerebellum with an anti–N-linked oligosaccharide
antibody from (c) 4.5-month-old double knockout and (d) 4.5-month-
old Hexb–/– single knockout mice. ×130. Arrows point out Purkinje cells.
H&E, hematoxylin and eosin.
sive storage of GSL substrates include Gaucher’s disease,
Fabry’s disease, and the activator deficiencies. In all these
cases, secondary storage diseases after GSL depletion
would not appear to be a concern.
GM1 gangliosidosis (β-galactosidase deficiency) (29),
like Sandhoff ’s disease, would have the potential for
developing a secondary storage disease after depletion of
GSLs. In GM1 gangliosidosis, oligosaccharides and pro-
teoglycans are stored along with GSLs and appear to
contribute significantly to the disease manifestations. In
the later onset forms of Sandhoff ’s disease and GM1 gan-
gliosidosis, which have residual levels of degrading activ-
ity, the role of non-GSL substrates in pathogenesis is not
known. The possibility exists that the residual enzyme
activity in the milder disease forms, while insufficient to
prevent GSL storage, may be capable of preventing the
storage of water-soluble substrates.
Deleterious effects of GSL depletion. Slowing the rate of GSL
synthesis may lower their levels in the plasma membrane
of cells. Although consequences of this GSL depletion are
unclear, the GalNAcT–/– mice provide some insight into
the effects of total elimination of most complex ganglio-
sides. The GalNAcT–/– mice have a normal life span and
develop a near normal nervous system with only subtle
conduction abnormalities (14). Recently, some degener-
ative changes in their axons and Schwann cells have been
noted (30). Male infertility also results from impaired
GSL synthesis. However, in the GalNAcT–/– mice, the
absence of certain gangliosides is absolute and occurs
throughout embryonic development. This would not be
the case in substrate deprivation therapy where reduction
of GSL levels are unlikely to be reduced completely and
where GSL reduction would be implemented after devel-
opment of the nervous system.
The effects of GSL depletion in a compromised CNS
may also be a concern. The 11-week-old double knockout
mice with no GSL accumulation were unexpectedly less
proficient on rotorod than the Hexb–/– GalNAcT+/– mice,
even though the mice heterozygous for the disrupted Gal-
NAcT allele were abnormally accumulating GSLs. A pos-
sible explanation is that the complete absence of complex
gangliosides in the double knockout mice may have ren-
dered CNS more sensitive to damaging effects of oligosac-
charide storage. These results suggest that complex gan-
gliosides may stabilize or protect the CNS from insult or
injury. Caution should be taken, however, in directly
extrapolating the results obtained in mice to humans.
The genetic model presented here validates the concept
that substrate deprivation therapy can be highly effective
in preventing or eliminating disease manifestations in a
GSL storage disorder. Although the model also illus-
trated some potential limitations in the approach, over-
all the results advance substrate deprivation therapy as a
new treatment paradigm for the GSL storage diseases.
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